Giorgio A, De Luca M. Conversion therapy for hepatocellular carcinoma to improve treatment strategies for intermediate and advanced stages. World J Clin Cases 2024; 12(28): 6241-6243 [PMID: PMC11362885 DOI: 10.12998/wjcc.v12.i28.6241]
Corresponding Author of This Article
Antonio Giorgio, MD, Chief Doctor, Athena Clinic Center, Via Matese 90, Piedimonte Matese (CE) 81016, Campania, Italy. agiorgio28@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Oct 6, 2024; 12(28): 6241-6243 Published online Oct 6, 2024. doi: 10.12998/wjcc.v12.i28.6241
Conversion therapy for hepatocellular carcinoma to improve treatment strategies for intermediate and advanced stages
Antonio Giorgio, Massimo De Luca
Antonio Giorgio, Athena Clinic Center, Via Matese, Piedimonte Matese (CE) 81016, Campania, Italy
Massimo De Luca, Liver Unit, AORN Cardarelli, Via A. Cardarelli, Napoli 80131, Campania, Italy
Co-first authors: Antonio Giorgio and Massimo De Luca.
Author contributions: Giorgio A and De Luca M conceived the presented idea, performed the study, and wrote the manuscript. Based on their equal knowledge of the clinical problem and bibliographical research, both authors merit co-first authorship.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Antonio Giorgio, MD, Chief Doctor, Athena Clinic Center, Via Matese 90, Piedimonte Matese (CE) 81016, Campania, Italy. agiorgio28@gmail.com
Received: May 13, 2024 Revised: July 14, 2024 Accepted: August 1, 2024 Published online: October 6, 2024 Processing time: 91 Days and 10.8 Hours
Abstract
This manuscript is based on a case reported by Song et al published in the World Journal of Clinical Cases. Several challenges remain in the field of hepatocellular carcinoma (HCC) conversion therapy. Consequently, only a limited number of patients with HCC accompanied by portal vein tumor thrombosis (PVTT) and hepatic vein tumor thrombosis (HVTT) are eligible for resection. This clinical case demonstrates that considering the complexity of the disease, a multimodal and multidisciplinary approach is essential for managing HCC accompanied by PVTT and HVTT. However, the outcomes of such surgeries remain controversial. In conclusion, research on HCC conversion therapy is extremely useful for improving treatment strategies for intermediate and advanced HCC, which currently have disappointing clinical outcomes.
Core Tip: Hepatocellular carcinoma accompanied by portal vein tumor thrombus and inferior vena cava tumor thrombus can be converted to surgical resection after multimodality and multidisciplinary treatments.
